These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 22102929)

  • 21. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic review and meta-analysis of randomized controlled trials comparing 17-alpha-hydroxyprogesterone caproate versus placebo for the prevention of recurrent preterm birth.
    Fernandez-Macias R; Martinez-Portilla RJ; Cerrillos L; Figueras F; Palacio M
    Int J Gynaecol Obstet; 2019 Nov; 147(2):156-164. PubMed ID: 31402445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Application of Progesterone for the Prevention of Preterm Birth, 2016.
    Goodnight W
    Am J Perinatol; 2016 Feb; 33(3):253-7. PubMed ID: 26788788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaginal progesterone is as effective as cervical cerclage to prevent preterm birth in women with a singleton gestation, previous spontaneous preterm birth, and a short cervix: updated indirect comparison meta-analysis.
    Conde-Agudelo A; Romero R; Da Fonseca E; O'Brien JM; Cetingoz E; Creasy GW; Hassan SS; Erez O; Pacora P; Nicolaides KH
    Am J Obstet Gynecol; 2018 Jul; 219(1):10-25. PubMed ID: 29630885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?
    Hall NR
    Obstet Gynecol Clin North Am; 2011 Jun; 38(2):235-46, ix-x. PubMed ID: 21575799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current Approaches to Risk Assessment and Prevention of Preterm Birth-A Continuing Public Health Crisis.
    Biggio JR
    Ochsner J; 2020; 20(4):426-433. PubMed ID: 33408582
    [No Abstract]   [Full Text] [Related]  

  • 27. Progesterone for Prevention of Preterm Birth: Shortcomings and Unintended Consequences of the Orphan Drug Act.
    Gee RE; Kuy S; Karas LO
    Obstet Gynecol; 2017 Dec; 130(6):1202-1206. PubMed ID: 29112651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of progesterone during pregnancy to prevent preterm birth.
    Alsulmi ES; Alfaraj M; Faden Y; Al Qahtani N
    Saudi Med J; 2020 Apr; 41(4):333-340. PubMed ID: 32291419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accelerated Approval of 17α-Hydroxyprogesterone Caproate: A Cautionary Tale.
    Godlewski BJ; Sobolik LI; King VJ; Harrod CS
    Obstet Gynecol; 2020 May; 135(5):1207-1213. PubMed ID: 32282587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progestogens and prevention of preterm birth in women at risk.
    Prescrire Int; 2016 Jul; 25(173):185-188. PubMed ID: 30730653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The rebirth of progesterone in the prevention of preterm labor.
    Schmouder VM; Prescott GM; Franco A; Fan-Havard P
    Ann Pharmacother; 2013 Apr; 47(4):527-36. PubMed ID: 23535817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 17α-hydroxyprogesterone caproate access in the Louisiana Medicaid population.
    Orsulak MK; Block-Abraham D; Gee RE
    Clin Ther; 2015 Apr; 37(4):727-32. PubMed ID: 25700945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ACOG Committee Opinion. Use of progesterone to reduce preterm birth.
    American College of Obstetricians and Gynecologists
    Obstet Gynecol; 2003 Nov; 102(5 Pt 1):1115-6. PubMed ID: 14672496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addressing Decision Making in Progesterone Treatment for History of Preterm Delivery.
    Zuponcic J; Cottrell C; Lavin J; Facchini W; Li M
    AJP Rep; 2019 Jul; 9(3):e244-e250. PubMed ID: 31435484
    [No Abstract]   [Full Text] [Related]  

  • 35. Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial.
    Price JT; Vwalika B; Freeman BL; Cole SR; Mulenga HB; Winston J; Mbewe FM; Chomba E; Mofenson LM; Rouse DJ; Goldenberg RL; Stringer JSA
    BMC Pregnancy Childbirth; 2019 Feb; 19(1):81. PubMed ID: 30813934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized controlled trial of intramuscular versus vaginal progesterone for the prevention of recurrent preterm birth.
    Elimian A; Smith K; Williams M; Knudtson E; Goodman JR; Escobedo MB
    Int J Gynaecol Obstet; 2016 Aug; 134(2):169-72. PubMed ID: 27168167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 17 α-Hydroxyprogesterone caproate (Makena™): in the prevention of preterm birth.
    Deeks ED
    Paediatr Drugs; 2011 Oct; 13(5):337-45. PubMed ID: 21888448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The value of oral micronized progesterone in the prevention of recurrent spontaneous preterm birth: a randomized controlled trial.
    Ashoush S; El-Kady O; Al-Hawwary G; Othman A
    Acta Obstet Gynecol Scand; 2017 Dec; 96(12):1460-1466. PubMed ID: 28949010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
    Odibo AO; Stamilio DM; Macones GA; Polsky D
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of 17 alpha-hydroxyprogesterone caproate in the prevention of preterm birth.
    Meis PJ
    Womens Health (Lond); 2006 Nov; 2(6):819-24. PubMed ID: 19803999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.